Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation… Read more
Recursion Pharmaceuticals Inc (RXRX) - Net Assets
Latest net assets as of September 2025: $1.05 Billion USD
Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) has net assets worth $1.05 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.40 Billion) and total liabilities ($352.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.05 Billion |
| % of Total Assets | 74.81% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 61.73 |
Recursion Pharmaceuticals Inc - Net Assets Trend (2019–2024)
This chart illustrates how Recursion Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Recursion Pharmaceuticals Inc (2019–2024)
The table below shows the annual net assets of Recursion Pharmaceuticals Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.03 Billion | +123.28% |
| 2023-12-31 | $463.44 Million | -4.60% |
| 2022-12-31 | $485.81 Million | -10.52% |
| 2021-12-31 | $542.94 Million | +363.19% |
| 2020-12-31 | $-206.29 Million | -66.01% |
| 2019-12-31 | $-124.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Recursion Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 130468800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $-7.64 Million | -0.74% |
| Other Components | $2.47 Billion | 239.05% |
| Total Equity | $1.03 Billion | 100.00% |
Recursion Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Recursion Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GS Holdings Corp
KO:078935
|
$1.67 Billion |
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
$1.67 Billion |
|
Xinhu Zhongbao Co Ltd
SHG:600208
|
$1.67 Billion |
|
Artivion Inc
NYSE:AORT
|
$1.68 Billion |
|
Bumi Resources Tbk
JK:BUMI
|
$1.67 Billion |
|
SSP Group PLC
PINK:SSPPF
|
$1.67 Billion |
|
Vidrala SA
MC:VID
|
$1.67 Billion |
|
Megacable Holdings S. A. B. de C. V
PINK:MHSDF
|
$1.67 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Recursion Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 463,436,000 to 1,034,782,000, a change of 571,346,000 (123.3%).
- Net loss of 463,661,000 reduced equity.
- New share issuances of 300,417,000 increased equity.
- Other comprehensive income decreased equity by 7,637,000.
- Other factors increased equity by 742,227,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-463.66 Million | -44.81% |
| Share Issuances | $300.42 Million | +29.03% |
| Other Comprehensive Income | $-7.64 Million | -0.74% |
| Other Changes | $742.23 Million | +71.73% |
| Total Change | $- | 123.28% |
Book Value vs Market Value Analysis
This analysis compares Recursion Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.88x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.75 | $3.32 | x |
| 2020-12-31 | $-1.24 | $3.32 | x |
| 2021-12-31 | $3.19 | $3.32 | x |
| 2022-12-31 | $2.77 | $3.32 | x |
| 2023-12-31 | $2.23 | $3.32 | x |
| 2024-12-31 | $3.77 | $3.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Recursion Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -44.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -788.02%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.40x
- Recent ROE (-44.81%) is below the historical average (-32.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -3654.30% | 0.02x | 0.00x | $-50.10 Million |
| 2020 | 0.00% | -2549.25% | 0.01x | 0.00x | $-66.38 Million |
| 2021 | -32.80% | -1780.74% | 0.02x | 1.12x | $-232.37 Million |
| 2022 | -49.28% | -603.36% | 0.06x | 1.44x | $-288.00 Million |
| 2023 | -70.79% | -747.71% | 0.07x | 1.41x | $-374.41 Million |
| 2024 | -44.81% | -788.02% | 0.04x | 1.40x | $-567.14 Million |
Industry Comparison
This section compares Recursion Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Recursion Pharmaceuticals Inc (RXRX) | $1.05 Billion | 0.00% | 0.34x | $1.67 Billion |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |